Imagine trying to design a key for a lock that is constantly changing its shape. That is the exact challenge we face in ...

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ...

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ...

Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAPY) stock at Seeking Alpha.

Adaptimmune Therapeutics has a price-to-earnings (P/E) ratio of -0.240 (TTM). This compares to an industry average of 25.990. The P/S ratio for Adaptimmune Therapeutics is currently 0.652 (TTM). What ...